[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fs4ri6ppsH4pWYrTjCrmw3rnv1iv6UlhdWjK1LcWQUns":8,"$fKvgpXuSoaxdL3x5_D-2_jTZDYJlJ8KKLLCHNfhrnBiA":55,"$f5q9PJR4SYTdVI44TLSSlJc1CbK4fWQC7SG1zA6lSK0A":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},66829,867263,[],"https://ystcdn.venuertc.com/medical/ystApp/0YbWrtsGnIVSTzEaDbtlD7CaJRSwuqG9.png","李会敏","临清市人民医院","老年病内科","住院医师",384,0,"信迪利单抗安全用药指南：聚焦关键细节","","https://ystcdn.venuertc.com/venue/AI/f182b5e6-67bc-467e-bea1-a3c2ee08354d.jpg","\u003Cdiv class=\"cindilimab-guide-container\">\n  \u003Ch2 class=\"cindilimab-title\" id=\"material_title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">信迪利单抗安全用药指南：聚焦关键细节\u003C/h2>\n  \u003Cdiv class=\"cindilimab-intro\">\n    \u003Cp>\n      说到信迪利单抗，这是一种被归类为“免疫检查点抑制剂”的注射用药，常见于多种肿瘤治疗方案中。它通过调节机体免疫系统让身体自身对抗异常细胞。实际使用时，这类新型药物的服用方法、注意事项和安全管理有着不少讲究。下面整理了7个核心用药细节，帮助您在全程使用信迪利单抗的过程中，更安心、更规范。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 剂型特点与用法要点 -->\n  \u003Csection class=\"cindilimab-section\" style=\"background:linear-gradient(90deg, #f9fbfd 70%, #e3f0fe 100%)\">\n    \u003Ch2 class=\"cindilimab-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 剂型、成分与使用方法 🧪\u003C/h2>\n    \u003Cdiv class=\"cindilimab-content\">\n      \u003Cul>\n        \u003Cli>\u003Cstrong>剂型与规格：\u003C/strong>信迪利单抗为无色至淡黄色澄明或微乳状注射液，一般每瓶含100mg/4ml（25mg/ml）。\u003C/li>\n        \u003Cli>\u003Cstrong>成分：\u003C/strong>主成分为信迪利单抗活性蛋白，不含防腐剂。\u003C/li>\n        \u003Cli>\u003Cstrong>给药方式：\u003C/strong>需静脉滴注，严禁皮下注射或肌内注射。 \n          \u003Cbr>正确做法：遵循医生指示，通常由专业医护人员在医疗机构内进行输注。\u003C/li>\n        \u003Cli>\u003Cstrong>用药频率：\u003C/strong>常见方案为每2-3周一次，单次滴注时间建议大于30分钟。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"cindilimab-tip\">\n        \u003Cspan>🔑\u003C/span> \u003Cspan>正确用药依赖于专业医疗人员操作，严禁自行注射。\u003C/span>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 药物作用机制简介 -->\n  \u003Csection class=\"cindilimab-section\" style=\"background:linear-gradient(90deg, #f5f7f6 75%, #ccebf4 100%)\">\n    \u003Ch2 class=\"cindilimab-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 信迪利单抗的作用机制简述 ⚙️\u003C/h2>\n    \u003Cdiv class=\"cindilimab-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>作用靶点：\u003C/strong>信迪利单抗是一种PD-1免疫检查点抑制剂。它阻断PD-1受体与其配体结合，从而恢复并增强T细胞的免疫功能。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>药理特点：\u003C/strong>通过减少瘤细胞的免疫逃逸，使机体免疫系统可以更好地识别和清除异常细胞。这类似“解锁”了免疫系统的“刹车”，令防御力得以释放。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>起效时间：\u003C/strong>部分患者用药后数周可见免疫系统指标变化，但疗效和反应时间因人而异。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"cindilimab-tip\">\n        \u003Cspan>💡\u003C/span> \u003Cspan>此机制决定了信迪利单抗与传统化疗、靶向药物的不同，副作用谱也不相同。\u003C/span>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 适应症及用药限定 -->\n  \u003Csection class=\"cindilimab-section\" style=\"background:linear-gradient(90deg, #f8faf8 75%, #eee7f2 100%)\">\n    \u003Ch2 class=\"cindilimab-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 适应症范围与禁忌要点 🛑\u003C/h2>\n    \u003Cdiv class=\"cindilimab-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>主要适应症：\u003C/strong>信迪利单抗被批准用于多种实体瘤的治疗。具体病种需按医生方案判定，勿自行判断适用性。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>禁忌人群：\u003C/strong>\n          \u003Cul>\n            \u003Cli>已知对本品任何成分过敏者严禁使用。\u003C/li>\n            \u003Cli>曾经发生严重免疫相关反应（如严重皮疹、肺炎、肝炎等）者禁用。\u003C/li>\n            \u003Cli>孕妇及哺乳期妇女禁用，因其对胎儿和婴儿安全性未确定。\u003C/li>\n            \u003Cli>自体免疫性疾病活动期、器官移植受者需极度谨慎。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"cindilimab-tip\">\n        \u003Cspan>⚠️\u003C/span> \u003Cspan>合理使用信迪利单抗需全面评估患者全身状况，如有禁忌务必告知医师。\u003C/span>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 用药用量与滴注注意事项 -->\n  \u003Csection class=\"cindilimab-section\" style=\"background:linear-gradient(90deg, #f7f8fa 80%, #f4ffe6 100%)\">\n    \u003Ch2 class=\"cindilimab-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 用药用量与滴注规范 📅\u003C/h2>\n    \u003Cdiv class=\"cindilimab-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>推荐剂量：\u003C/strong>成人推荐剂量为每次200mg或固定方案，每2-3周静滴一次，具体以说明书和医生评估为准。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>滴注要求：\u003C/strong>滴注时间通常不少于30分钟，严格避免推注或快滴。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>方案调整：\u003C/strong>因体重、总体健康状况不同，老年人等特殊人群可能需个体调整，必须由医生根据具体情况评估。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"cindilimab-tip\">\n        \u003Cspan>⏰\u003C/span> \u003Cspan>每次用药后，应观察至少1小时，便于及早发现输注反应。\u003C/span>\n      \u003C/div>\n      \u003Cdiv class=\"cindilimab-case\">\n        \u003Cspan>案例：\u003C/span>\u003Cspan>有位高龄女性于免疫联合治疗时在院规范输注信迪利单抗，因未能及时调整既往化疗方案，出现严重骨髓抑制，后续巩固治疗期间密切随访，耐受性恢复良好。\u003C/span>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 药物相互作用关注点 -->\n  \u003Csection class=\"cindilimab-section\" style=\"background:linear-gradient(90deg, #f7f9fe 65%, #e6fff7 100%)\">\n    \u003Ch2 class=\"cindilimab-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 药物相互作用须知 🤝\u003C/h2>\n    \u003Cdiv class=\"cindilimab-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>常见相互作用：\u003C/strong>\n          \u003Cul>\n            \u003Cli>联合免疫调节药（如免疫抑制剂，如激素、大剂量糖皮质激素）可能降低疗效。\u003C/li>\n            \u003Cli>接受化疗药物时，部分药物（如紫杉醇类、铂类等）可增加副作用，需要严密监测。\u003C/li>\n            \u003Cli>多药联用时，须向医生详细报告所有药品，包括中草药和非处方药。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>与疫苗接种的关系：\u003C/strong>说明书提示，信迪利单抗期间不建议接种活疫苗，以免诱发异常免疫反应。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"cindilimab-tip\">\n        \u003Cspan>🔗\u003C/span> \u003Cspan>如有新增用药需提前知会医务人员，避免潜在用药冲突。\u003C/span>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 常见不良反应与处理 -->\n  \u003Csection class=\"cindilimab-section\" style=\"background:linear-gradient(90deg, #f6f8fb 85%, #fef6ee 100%)\">\n    \u003Ch2 class=\"cindilimab-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 常见不良反应及管理 📝\u003C/h2>\n    \u003Cdiv class=\"cindilimab-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>免疫相关不良反应：\u003C/strong>常见有皮疹、乏力、发热、关节痛；也可能出现免疫性肺炎、肝炎、肠炎、内分泌紊乱等。 \n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>骨髓抑制与感染：\u003C/strong>免疫联用化疗期间，有导致白细胞减少、易感染风险。需密切血常规监测。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>发现副作用的处理：\u003C/strong>\n            出现异常如持续发热、皮疹、腹泻、气促、剧烈乏力、黄疸等症状时，立即就医并报告医生，切勿自行停药或延误处理。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"cindilimab-tip\">\n        \u003Cspan>🚨\u003C/span> \u003Cspan>临床数据显示，免疫相关不良反应发生率在10%-30%区间，绝大多数不良反应可逆，早期识别和处理极为关键（Sharma et al., Nature Reviews Drug Discovery, 2021）。\u003C/span>\n      \u003C/div>\n      \u003Cdiv class=\"cindilimab-case\">\n        \u003Cspan>案例：\u003C/span>\u003Cspan>临床上联合免疫化疗时，患者曾因白细胞降低接受隔离监护、暂停部分药物，最终安全过渡至巩固阶段。\u003C/span>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 储存条件与有效期 -->\n  \u003Csection class=\"cindilimab-section\" style=\"background:linear-gradient(90deg, #eef9f7 70%, #edebfc 100%)\">\n    \u003Ch2 class=\"cindilimab-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 储存要求与用药安全 ⛄\u003C/h2>\n    \u003Cdiv class=\"cindilimab-content\">\n      \u003Cul>\n        \u003Cli>\u003Cstrong>保存环境：\u003C/strong>信迪利单抗需保存在2-8℃冷藏环境，避免冷冻，不可暴晒。\u003C/li>\n        \u003Cli>\n          \u003Cstrong>运输要求：\u003C/strong>整个流通过程冷链管理，临床使用前由医疗机构按需调配。\n        \u003C/li>\n        \u003Cli>\u003Cstrong>过期处理：\u003C/strong>未用完的药物应按医疗废弃物规范处理，不得自行丢弃。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"cindilimab-tip\">\n        \u003Cspan>📦\u003C/span> \u003Cspan>药品应避免反复拿出冷藏，温度波动会影响活性，切勿自行储存和携带。\u003C/span>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 漏服与过量处理小节 -->\n  \u003Csection class=\"cindilimab-section\" style=\"background:linear-gradient(90deg, #f9fafb 85%, #ffe4e6 100%)\">\n    \u003Ch2 class=\"cindilimab-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 漏服和过量如何应对？⏳\u003C/h2>\n    \u003Cdiv class=\"cindilimab-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>漏服处理：\u003C/strong>如未按计划用药，应尽早联系医务人员，并根据医生安排重新预约滴注时间。不可补发双倍剂量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>过量风险：\u003C/strong>尚无特效解毒药。大量用药可能导致更严重免疫紊乱，出现持续发热、皮肤表现、呼吸系统症状等异常需紧急就医。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"cindilimab-tip\">\n        \u003Cspan>📱\u003C/span> \u003Cspan>信迪利单抗的全流程管理需专科随访，切忌擅自调整用药计划。\u003C/span>\n      \u003C/div>\n      \u003Cdiv class=\"cindilimab-case\">\n        \u003Cspan>案例：\u003C/span>\u003Cspan>一位肿瘤患者因家庭变故错过滴注时间，后及时沟通补齐疗程，未因漏服导致严重问题。\u003C/span>\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 总结与安全使用提醒 -->\n  \u003Csection class=\"cindilimab-section\" style=\"background:linear-gradient(90deg, #f7faf7 90%, #e3ecfa 100%)\">\n    \u003Ch2 class=\"cindilimab-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">总结与用药安全提示 ☑️\u003C/h2>\n    \u003Cdiv class=\"cindilimab-content\">\n      \u003Cp>\n        总结来看，信迪利单抗属于高风险、高价值的免疫治疗药物，必须经医生评估后严格规范使用。每一个疗程、每一次注射，都离不开专业人员的严谨管理。请记住：\u003Cbr>\n        \u003Cstrong style=\"color:#3764a7;\">1. 绝不能私自储存、注射及调整药量。\u003C/strong>\n        \u003Cbr>\n        \u003Cstrong style=\"color:#3764a7;\">2. 若联合用药、出现不良反应、特殊人群（如高龄、肝肾功能异常）需额外关注医生建议。\u003C/strong>\n        \u003Cbr>\n        安全用药，需要来自专业团队和患者及家属的共同配合。遇到疑惑和异常，毫不犹豫地及时与医护团队沟通，就是保护健康的最佳办法。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 参考文献 -->\n  \u003Csection class=\"cindilimab-section\" style=\"background:linear-gradient(90deg, #e7e7ee 70%, #f7f7fb 100%)\">\n    \u003Ch2 class=\"cindilimab-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献📚\u003C/h2>\n    \u003Col class=\"cindilimab-ref-list\">\n      \u003Cli>\n        Sharma, P., & Allison, J. P. (2021). Immune checkpoint therapy: current perspectives and future directions. \u003Cem>Nature Reviews Drug Discovery, 20\u003C/em>(7), 527-547. https://doi.org/10.1038/s41573-021-00194-1\n      \u003C/li>\n      \u003Cli>\n        Wang, F., et al. (2019). Safety and Efficacy of Sintilimab in Chinese Patients With Advanced Solid Tumors: A Phase I Study. \u003Cem>Cancer Immunology, Immunotherapy, 68\u003C/em>(8), 1257–1266.\n      \u003C/li>\n      \u003Cli>\n        Chen, Y., & Yu, Z. (2020). Safety and tolerability of immune checkpoint inhibitors. \u003Cem>Journal of Hematology & Oncology, 13\u003C/em>(1), 25. https://doi.org/10.1186/s13045-020-00861-5\n      \u003C/li>\n    \u003C/ol>\n  \u003C/section>\n\u003C/div>\n\n\n\u003Cstyle>\n.cindilimab-guide-container {\n  max-width: 820px;\n  margin: 36px auto;\n  font-family: 'Segoe UI', 'Arial', sans-serif;\n  background: #f8fafd;\n  border-radius: 12px;\n  box-shadow: 0 2px 16px rgba(51,92,181,0.08);\n  padding: 16px 22px 30px 22px;\n  box-sizing: border-box;\n}\n\n.cindilimab-title {\n  font-size: 2.3em;\n  color: #244178;\n  margin: 18px 0 12px 0;\n  text-align: center;\n  letter-spacing: 1px;\n  font-weight: bold;\n}\n\n.cindilimab-intro {\n  font-size: 1.18em;\n  color: #304360;\n  margin: 8px auto 22px auto;\n  background: #e3f0fe;\n  border-radius: 8px;\n  padding: 15px 20px 10px 18px;\n  box-shadow: 0 2px 8px rgba(78,140,238,0.07);\n}\n\n.cindilimab-section {\n  margin-top: 29px;\n  margin-bottom: 26px;\n  border-radius: 12px;\n  padding: 22px 18px 18px 18px;\n  box-shadow: 0 1px 8px rgba(65,110,175,0.05);\n}\n\n.cindilimab-subtitle {\n  font-size: 1.48em;\n  font-weight: 600;\n  margin-bottom: 14px;\n  color: #3161ad;\n  background: linear-gradient(90deg, #f5fafd 60%, #f0eafa 100%);\n  padding: 7px 18px;\n  border-radius: 8px;\n}\n\n.cindilimab-content {\n  font-size: 1.08em;\n  color: #212a39;\n  margin-top: 9px;\n}\n\n.cindilimab-content ul {\n  padding-left: 19px;\n  margin-bottom: 16px;\n}\n\n.cindilimab-content ul li {\n  line-height: 1.7em;\n  margin-bottom: 7px;\n}\n\n.cindilimab-tip {\n  background: #e9f4fb;\n  color: #2f4356;\n  padding: 7px 13px;\n  border-radius: 7px;\n  margin: 9px 0 6px 0;\n  display: flex;\n  align-items: center;\n  font-size: 1em;\n  font-style: italic;\n  gap: 8px;\n}\n\n.cindilimab-case {\n  background: #f7f1e9;\n  color: #49413d;\n  padding: 6px 12px 5px 13px;\n  border-radius: 6px;\n  margin: 8px 0 2px 0;\n  font-size: 0.98em;\n  font-style: normal;\n}\n\n.cindilimab-ref-list {\n  list-style-type: decimal;\n  font-size: 1em;\n  color: #5d5674;\n  margin-top: 9px;\n  padding-left: 25px;\n  margin-bottom: 0;\n}\n\n.cindilimab-ref-list li {\n  margin-bottom: 6px;\n}\n\n@media (max-width: 720px) {\n  .cindilimab-guide-container {\n    padding: 9px 3% 20px 3%;\n  }\n  .cindilimab-title {\n    font-size: 1.35em;\n  }\n  .cindilimab-section {\n    padding: 7px 5px 10px 9px;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"cindilimab-guide-container\">\n  \u003Ch2 class=\"cindilimab-title\" id=\"material_title\" style=\"c",538,"2025-09-19 13:57:14","信迪利单抗, 安全用药, 免疫检查点抑制剂, 不良反应, 用药指南","了解信迪利单抗的安全用药指南，确保免疫治疗的效益和安全。本文深入解析信迪利单抗的适应症、用法、注意事项及不良反应，帮助患者更好地配合专业医疗团队。","2025-10-15 00:00:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]